Science 37 Holdings, Inc. (SNCE) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Science 37 Holdings, Inc. (SNCE) Healthcare & Pipeline Overview

Science 37 Holdings, Inc. pioneers decentralized clinical trial solutions, leveraging a proprietary cloud-based platform to connect patients, investigators, and sponsors. This technology facilitates agile, digital research across various medical indications, enhancing data generation and workflow standardization for pharmaceutical and biotech clients.

What Is the Investment Thesis for SNCE?

Science 37 Holdings, Inc. presents an investment case centered on its specialized position within the rapidly expanding decentralized clinical trial (DCT) market, driven by its proprietary technology platform. The company's ability to facilitate agile, patient-centric research through integrated networks and a highly configurable cloud-based solution addresses critical inefficiencies in traditional clinical trials. Key value drivers include the increasing industry shift towards DCTs, which enhance patient access and reduce operational costs, positioning Science 37 as an enabler of this transformation. The company's platform, which centralizes data generation and harmonizes workflows for diverse stakeholders, offers a scalable solution for pharmaceutical, biotech, and CRO clients. However, the investment thesis is tempered by significant financial considerations. Science 37 currently operates with a negative profit margin of -72.7%, indicating substantial ongoing losses, and a relatively low gross margin of 22.6%. Its market capitalization stands at a modest $0.03 billion, classifying it as a micro-cap entity, which may imply higher volatility, as partially reflected by its Beta of 0.56. Future growth catalysts hinge on the broader adoption of DCTs, successful expansion of its platform licensing agreements, and the ability to convert its technological leadership into sustained profitability. Investors would monitor the company's progress in improving financial performance and scaling its operations within a competitive healthcare technology landscape.

Based on FMP financials and quantitative analysis

SNCE Key Highlights

• Market Capitalization: $0.03 billion, indicating a micro-cap company within the healthcare information services sector.
• Profit Margin: -72.7%, reflecting significant operational losses and challenges in achieving profitability.
• Gross Margin: 22.6%, suggesting a moderate margin on services before accounting for operating expenses.
• Beta: 0.56, indicating lower volatility compared to the broader market, potentially due to its specialized niche.
• Employee Count: 460 employees, supporting its specialized technology development and service offerings for clinical trials.

Who Are SNCE's Competitors?

SNCE is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are SNCE's Key Strengths?

• Proprietary, highly configurable cloud-based platform for decentralized clinical trials (DCTs).
• Integrated networks of specialized resources including telemedicine investigators and mobile nurses.
• Ability to support virtually any phase and indication of clinical studies, offering broad applicability.
• Established client base including major pharmaceutical companies, CROs, and biotech firms.

What Are SNCE's Weaknesses?

• Persistent negative profit margin of -72.7%, indicating significant operational losses.
• Relatively small market capitalization of $34.7M, potentially limiting capital access.
• Reliance on the continued adoption and regulatory acceptance of decentralized clinical trial methodologies.
• Moderate gross margin of 22.6%, suggesting cost pressures before operating expenses.

What Could Drive SNCE Stock Higher?

• Increasing adoption of decentralized clinical trial methodologies across the pharmaceutical and biotech industries, driving demand for Science 37's platform.
• Potential for new strategic partnerships with major pharmaceutical companies or Contract Research Organizations (CROs) to expand platform utilization and market reach.
• Introduction of enhanced platform features or new service offerings designed to address evolving clinical research needs and improve trial efficiency.
• Expansion of the company's proprietary technology licensing agreements with various life science institutions, providing scalable revenue streams.

What Are the Key Risks for SNCE?

• Financial-distress signal — its Altman Z-Score of -3.18 sits in the distress zone (elevated bankruptcy risk).
• Negative return on equity (-46.6%) — the business is not currently generating profit on shareholder capital.
• Sustained negative profit margin of -72.7% indicating challenges in achieving profitability and operational efficiency.
• Intense competition from larger, more established Contract Research Organizations (CROs) and other health technology providers in the decentralized trial space.
• Regulatory changes or evolving data privacy standards impacting the execution and acceptance of decentralized clinical trials globally.
• Reliance on continued investment in research and development to maintain technological edge in a rapidly evolving healthcare technology market.
• Small market capitalization of $34.7M potentially limiting access to capital for future growth initiatives and operational scaling.

What Are the Growth Opportunities for SNCE?

• Expansion of Decentralized Clinical Trials (DCTs): The global market for decentralized clinical trials is projected to grow significantly, driven by benefits such as improved patient access, reduced site burden, and enhanced data quality. Science 37's core business is directly aligned with this trend, offering a comprehensive platform that facilitates remote patient engagement, data collection, and virtual trial management. As pharmaceutical and biotech companies increasingly adopt DCT models to accelerate drug development and lower costs, Science 37 is well-positioned to capture a larger share of this expanding market, with adoption expected to continue growing over the next 5-10 years.
• Increased Platform Licensing: Beyond direct trial services, Science 37 licenses its proprietary, cloud-based technology platform to various life science institutions. This represents a scalable growth opportunity, allowing the company to generate recurring revenue without directly managing every trial. By expanding its licensing agreements with large pharmaceutical companies, CROs, and academic research centers, Science 37 can broaden its market reach and embed its technology deeper into the clinical research ecosystem. This strategy offers a higher-margin revenue stream and strengthens its position as a foundational technology provider in the industry, with potential for significant uptake over the next 3-7 years.
• Broadening Therapeutic Area Support: The Science 37 platform is designed to be highly configurable, supporting virtually any phase of a clinical study and a wide range of medical indications. This adaptability allows the company to pursue growth by expanding its services into new therapeutic areas, including rare diseases, oncology, and chronic conditions, where patient access and geographic diversity are particularly critical. By demonstrating success across diverse indications, Science 37 can attract a broader client base and increase the utilization of its platform, tapping into specialized markets with unmet clinical trial needs over the medium to long term (3-10 years).
• Strategic Partnerships with CROs and Pharma: Forming strategic alliances with major Contract Research Organizations (CROs) and large pharmaceutical companies presents a significant growth avenue. Such partnerships can lead to deeper integration of Science 37's platform into larger, more complex clinical programs, leveraging the partners' extensive client networks and trial volumes. These collaborations can accelerate market penetration, validate the platform's capabilities on a larger scale, and provide access to substantial, long-term contracts. Joint ventures or preferred provider agreements could solidify Science 37's market position and drive substantial revenue growth over the next 2-5 years.
• Technological Enhancements and AI Integration: Continuous innovation in its technology platform, including the integration of advanced analytics, machine learning, and artificial intelligence, offers a compelling growth opportunity. Enhancing the platform's capabilities for predictive analytics, real-time data insights, and automated workflow optimization can improve trial efficiency, data quality, and decision-making for clients. These technological advancements can strengthen Science 37's competitive advantage, attract new clients seeking cutting-edge solutions, and potentially create new revenue streams through premium features or data services. This ongoing innovation is critical for sustained growth over the next 5-10 years.

What Opportunities Does SNCE Have?

• Growing global market for decentralized clinical trials, driven by efficiency and patient access benefits.
• Expansion of platform licensing agreements to a broader range of life science institutions.
• Strategic partnerships with larger pharmaceutical companies and Contract Research Organizations (CROs).
• Further technological enhancements and integration of advanced analytics or AI into the platform.

What Threats Does SNCE Face?

• Intense competition from larger, more established Contract Research Organizations (CROs) developing their own DCT capabilities.
• Potential for evolving regulatory landscapes or data privacy concerns impacting decentralized trial execution.
• Economic downturns or shifts in R&D spending by pharmaceutical and biotech clients.
• Challenges in maintaining technological leadership in a rapidly innovating healthcare technology market.

What Are SNCE's Competitive Advantages?

• Proprietary, highly configurable cloud-based technology platform specifically designed for end-to-end decentralized clinical trials.
• Integrated network of specialized resources including patient communities, telemedicine investigators, mobile nurses, and remote coordinators.
• Early mover advantage and deep specialization in the rapidly evolving decentralized clinical trial market segment.
• Comprehensive solution covering workflow management, centralized data generation, and harmonization across all trial stakeholders.

What Does SNCE Do?

Science 37 Holdings, Inc., established in 2014 and headquartered in Research Triangle Park, North Carolina, is a pioneering force in the healthcare information services sector, specifically focusing on technology solutions for flexible and decentralized clinical trials (DCTs). The company's core offering is a proprietary, cloud-based platform designed to revolutionize traditional clinical research by bringing together all essential stakeholders digitally. This includes patients, trial investigators, nurses, remote coordinators, and sponsors, all integrated into a unified ecosystem. The platform's primary function is to streamline workflows, centralize evidence generation, and harmonize data across diverse study participants and locations. Science 37's innovative approach extends beyond mere connectivity; its platform also provides specialized networks crucial for orchestrating agile clinical studies. These networks encompass dedicated patient communities, telemedicine-enabled investigators who can conduct virtual visits, mobile nursing professionals capable of in-home care, and remote coordinators who manage trial logistics from a distance. Furthermore, the integration of connected health devices allows for continuous, real-time data collection, enhancing the richness and accuracy of study outcomes. The platform's highly configurable architecture is a key differentiator, enabling it to support virtually any phase of a clinical study, from early-stage trials to post-market surveillance, and across a wide spectrum of medical indications. This adaptability makes it a versatile tool for various research needs. In addition to providing direct services for clinical trials, Science 37 also strategically licenses its advanced technology platform to a broad array of life science institutions. Its diverse client base includes major and mid-sized pharmaceutical companies, Contract Research Organizations (CROs), academic institutions engaged in medical research, and biotechnology firms, all seeking more efficient and patient-centric trial methodologies.

What Products and Services Does SNCE Offer?

• Provides technology solutions to enable flexible and decentralized clinical trials.
• Connects patients, trial investigators, nurses, coordinators, and sponsors through a central platform.
• Streamlines clinical research workflows and centralizes evidence generation.
• Harmonizes data from various sources to standardize information across trials.
• Offers specialized networks including patient communities, telemedicine investigators, and mobile nursing professionals.
• Integrates connected health devices for remote data collection in clinical studies.
• Licenses its proprietary, cloud-based technology platform to life science institutions.
• Supports virtually any phase of a clinical study and a wide range of medical indications.

How Does SNCE Make Money?

• Generates revenue through fees for technology solutions and services provided for decentralized clinical trials.
• Earns licensing fees from its proprietary cloud-based technology platform, utilized by various life science institutions.
• Secures service contracts with large and mid-sized pharmaceutical companies, Contract Research Organizations (CROs), academic institutions, and biotechnology firms for trial execution and support.

What Industry Does SNCE Operate In?

Science 37 Holdings, Inc. operates within the Medical - Healthcare Information Services industry, specifically targeting the burgeoning market for decentralized clinical trials (DCTs). This sector is experiencing significant growth driven by a global shift towards more efficient, patient-centric, and geographically flexible clinical research methodologies, a trend accelerated by technological advancements and recent global health events. The competitive landscape includes traditional Contract Research Organizations (CROs) that are increasingly developing their own DCT capabilities, as well as other specialized health technology providers. Science 37 differentiates itself by offering a comprehensive, proprietary, cloud-based platform that integrates all aspects of a DCT, from patient engagement to data harmonization. Its position as a dedicated technology enabler for DCTs allows it to capitalize on the increasing demand for remote and digital trial solutions, positioning it as a key player in modernizing clinical development processes.

Who Are SNCE's Key Customers?

• Large and mid-sized pharmaceutical companies seeking efficient clinical trial solutions.
• Contract Research Organizations (CROs) looking to enhance their service offerings with decentralized capabilities.
• Academic institutions conducting medical research and clinical studies.
• Biotechnology firms requiring agile and scalable platforms for drug development.

ROE -47%Key Financial Metrics

Return on equity for Science 37 Holdings, Inc. stands at -46.6%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -40.3%, showing how much profit it generates from its asset base. A current ratio of 5.45 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -7.7%, the inverse of the P/E and a quick read on earnings relative to price.

How Science 37 Holdings, Inc. Is Valued

Science 37 Holdings, Inc. carries a market capitalization of $34.7M, placing it in the micro-cap category. Relative to its peer group, SNCE's quantitative score of 48/100 is below the peer average of 61/100.

F-Score 4/9Financial Health

Science 37 Holdings, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -3.18 places it in the distress zone, a signal of elevated financial risk.

FY2026 estForward Outlook

Wall Street analysts project Science 37 Holdings, Inc. revenue of about $109.5M for fiscal 2026, with EPS near $0.40. The estimate reflects 3 contributing analysts.

SNCE Financials

SNCE Latest News

No recent news available for SNCE.

SNCE Analyst Consensus

SNCE MoonshotScore

Science 37 Holdings, Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources